Author: Sarah Chavez, Director of IVD and Scientific Writing Services
Regulatory developments published October 2–9, 2026
Four FDA final orders published this week offer practical insights for teams developing IVD performance evidence. They address hereditary-cancer sequencing, molecular STI testing with home-collected specimens, hematopoietic-cell enrichment, and clinical-toxicology testing.
These developments have different implications. Three orders codify device classifications originally granted in 2023, while the fourth expands existing exemptions from premarket notification. For evidence teams, the value lies in understanding the specific studies, documentation, and intended-use boundaries that support each pathway.
Hereditary-cancer sequencing: connect analytical performance with clinical interpretation
Effective October 6, FDA codified the Class II classification and special controls for high-throughput DNA sequencing systems used in hereditary-cancer predisposition assessment. The original classification was granted on September 29, 2023.
The controls address genomic coverage, the clinical significance of included genes, specimen requirements, DNA quality, variant-calling thresholds, software validation, test failures, and procedures for interpreting and classifying variants. These prescription systems remain subject to 510(k) requirements and fall within a defined intended use that excludes screening, prenatal testing, and stand-alone diagnosis.
For manufacturers developing parallel FDA and IVDR evidence packages, the practical implication is to connect assay performance with the interpretation process. A useful evidence map should show how each claimed gene and variant type is supported, how the analytical pipeline performs, and how detected findings become clinically meaningful results.
Regulatory reference: 21 CFR 866.6095; Docket FDA-2026-N-10990; 91 FR 63487, October 6, 2026. Official order.
Home-collected STI specimens: validate the complete testing pathway
FDA’s October 9 order codifies Class II special controls for laboratory molecular tests using home-collected specimens to detect non-viral microorganisms causing sexually transmitted infections. The original classification was granted in November 2023.
The controls require prospective clinical studies using self-collected samples for each claimed specimen type, an appropriate comparator, and a predefined statistical analysis plan. They also address analytical performance, usability, label comprehension, and specimen integrity during handling and shipping.
For clinical-performance planning, this reinforces the importance of evaluating the conditions under which patients actually collect and transport specimens. Teams can use these controls to assess whether their evidence adequately covers collection errors, shipping conditions, specimen acceptance, and performance in the intended population.
Regulatory reference: 21 CFR 866.3385; Docket FDA-2026-N-10996; 91 FR 64611, October 9, 2026. Published order.
Hematopoietic-cell enrichment: make pre-analytical performance visible
Also effective October 9, FDA codified the Class II classification for immunomagnetic hematopoietic-cell enrichment kits used with blood or bone marrow from patients with hematological malignancies. The classification was originally granted in November 2023.
The special controls address recovery, limit of detection, reproducibility, and specimen stability, with evidence covering claimed specimen-type and malignancy combinations. Labeling must identify the end user’s responsibility to validate the enrichment device with the downstream assay.
The practical lesson for performance-evaluation teams is to document the contribution of sample preparation explicitly. Evidence tables should distinguish enrichment performance from downstream assay performance and identify where compatibility testing is needed. This makes it easier to assess whether results support the complete claimed workflow.
Regulatory reference: 21 CFR 866.6120; Docket FDA-2026-N-10994; 91 FR 64609, October 9, 2026. Published order.
Clinical-toxicology testing: reassess the submission pathway against intended use
FDA’s October 6 order expands existing 510(k) exemptions for specified clinical-toxicology test systems to include qualifying uses in Federal drug-testing programs. Eligibility remains subject to limitations, including labeling restricting the intended use to employment and insurance testing. Applicable quality-system, labeling, and reporting obligations continue.
Manufacturers should therefore check the exact assay type, product code, claims, and labeling before changing their submission plans. The exemption concerns premarket notification; it does not establish a blanket exemption for diagnostic or treatment-monitoring uses, or remove the need to substantiate performance claims.
Regulatory reference: Docket FDA-2026-N-4268; 91 FR 63478, October 6, 2026. Official order.
For IVDR teams, these FDA orders provide useful comparators when reviewing evidence plans and identifying gaps. Their application to a European performance evaluation remains an assessment decision: each requirement should be evaluated against the device’s intended purpose, claims, workflow, and applicable IVDR obligations. The immediate opportunity is to revisit evidence maps and confirm that every step influencing the reported result has appropriate support.
